Viridian Therapeutics
VRDN
39 hedge funds and large institutions have $224M invested in Viridian Therapeutics in 2021 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 16 increasing their positions, 3 reducing their positions, and 3 closing their positions.
433% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 3
433% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 3
104% more capital invested
Capital invested by funds: $110M → $224M (+$114M)
50% more funds holding
Funds holding: 26 → 39 (+13)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
15.03% more ownership
Funds ownership: 71.22% → 86.24% (+15%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
+$22.1M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$22M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$19.1M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
+$13.3M |
| 5 |
PA
Perceptive Advisors
New York
|
+$9.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.6M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$4.57M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$2.19M |
| 4 |
B
Bailard
Foster City,
California
|
-$1.66M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$5.87K |
VRDN Hedge Fund Activity: Q3 2021 in Review
39 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Viridian Therapeutics (VRDN) for Q3 2021, worth a combined $224M — up 104% from $110M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new VRDN positions and 3 closed out — a net gain of 13 holders — while 16 added to existing stakes and 3 trimmed.
The largest buyer was Frazier Management, opening a new position worth an estimated $22.1M. The largest seller was Wellington Management Group, exiting entirely with an estimated $10.6M sold.
- 39 institutional investors held Viridian Therapeutics (VRDN) as of Q3 2021, up from 26 in Q2 2021.
- Funds reported $224M of Viridian Therapeutics stock for Q3 2021, up 104% quarter-over-quarter.
- 16 funds opened new Viridian Therapeutics positions in Q3 2021 and 3 closed out, a net change of +13 holders.
- The largest Viridian Therapeutics buyer in Q3 2021 was Frazier Management, an estimated $22.1M added.
- The largest Viridian Therapeutics seller in Q3 2021 was Wellington Management Group, an estimated $10.6M sold.
Based on aggregated 13F filings for Q3 2021.